和黃醫藥(00013.HK)將於歐洲腫瘤內科學會年會公布(口夫)(口奎)替尼最新數據
和黃醫藥(00013.HK)公布,將於本月20日至24日在西班牙馬德里召開的2023年歐洲腫瘤內科學會(ESMO)年會上,公布(口夫)(口奎)替尼(fruquintinib)聯合化療或免疫療法的最新臨床數據。
公司指,(口夫)(口奎)替尼是一種選擇性的口服VEGFR-1、-2及-3抑制劑。VEGFR抑制劑在抑制腫瘤的血管生成中起到至關重要的作用。迄今為止,(口夫)(口奎)替尼在患者中的耐受性普遍良好。(口夫)(口奎)替尼於2018年9月獲中國國家藥品監督管理局批准在中國銷售,並於2018年11月以商品名愛優特(ELUNATE)商業上市。
(口夫)(口奎)替尼向美國食品和藥物管理局(FDA)提交的上市申請獲予以優先審評,處方藥用戶付費法案(PDUFA)目標審評日期為11月30日。此外,向歐洲歐洲藥品管理局(EMA)提交的申請已於6月獲確認和受理,並已於9月向日本醫藥品和醫療器械局(PMDA)提交申請。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.